A survey by PSG has found that the pressure to control drug costs is leading some payers to look into unbundling pharmacy ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

CVS Caremark identified GLP-1 drugs and Humira as points of contention, but the State Health Plan says that mischaracterizes ...

A roundup of the most newsworthy healthcare press releases from PR Newswire, including Sanofi's $20B investment, Novo Nordisk's new initiatives for ...

With thousands of press releases published each month, it can be difficult to keep up with everything on PR Newswire. To help ...

Some Blue Cross and Blue Shield insurers dipped their toes into expanding coverage for blockbuster weight-loss drugs, then ...

Fifteen Connecticut companies made the 2025 Fortune 500 list of the largest U.S. corporations, which was announced Monday-- a sign of stability in the state's corporate sector. Bloomfield- ...

While employers aren’t yet reimbursing weight loss drugs en masse, significantly reduced net costs could affect their future ...

Investors flocked to shares of NRG as the energy supplier boosted capacity. UnitedHealth stock slumped, and the company’s CEO resigned.

Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.

Novo Nordisk's early lead in weight-loss drugs fades as Eli Lilly surges ahead with more effective therapies and faster manufacturing, shaking up the $150-bn obesity market ...

The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a ...